|Other names||Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123|
|Molar mass||1166.12 g mol−1|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)|
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).
Phase II clinical trials were in progress in 1999.